I just read something interesting, dolutegravir is recommend for children by WHO. Dolutegravir attempted mono but the trial failed. It would seem the most logical choice to use leronimab first because it gives less side effects and is least likely to find resistance (their mono trial was cancelled because there was some resistance). I wonder if that is why the FDA asked for mono pediatric info for the Combo BLA, to use leronlimab as mono as the first or early option in kids... Seems a likely reason to me.

https://www.msf.org/pfizer-and-gsk%E2%80%99s-...d-medicine

Quote:

---

The World Health Organization (WHO) now recommends dolutegravir as a preferred treatment option for adults and for children from four weeks to ten years of age, to replace pediatric treatments containing sub-optimal drugs with more side effects. When starting treatment, children need access to the best and most robust medicines possible – which are least likely to result in resistance – given they will likely take HIV medicines for life.

Treating HIV and AIDS in Conakry
HIV/AIDS
MSF at AIDS 2018
Project Update 16 Jul 2018

“The nearly two million babies and kids around the world who live with HIV shouldn’t have to settle for inferior treatment when something better exists,” said Dr David Maman, medical coordinator for MSF in Malawi. “It’s outrageous that ViiV is dragging its feet when it comes to getting better treatment for children with HIV.”

---